Bioverativ Inc (NASDAQ:BIVV) has been given an average rating of “Hold” by the fourteen ratings firms that are currently covering the firm, Marketbeat reports. Twelve research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $64.20.
Several equities analysts have recently issued reports on the stock. William Blair reissued a “hold” rating on shares of Bioverativ in a report on Thursday, March 8th. Credit Suisse Group reissued a “neutral” rating on shares of Bioverativ in a report on Wednesday, January 24th. Argus reaffirmed a “hold” rating on shares of Bioverativ in a research note on Wednesday, January 24th. Piper Jaffray lowered shares of Bioverativ from an “overweight” rating to a “neutral” rating in a research note on Monday, January 22nd. Finally, Royal Bank of Canada upped their target price on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a research note on Thursday, January 18th.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rehmann Capital Advisory Group acquired a new position in Bioverativ in the 4th quarter worth $241,000. Xact Kapitalforvaltning AB acquired a new position in Bioverativ in the 4th quarter worth $547,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its position in Bioverativ by 356.0% during the 4th quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 38,300 shares of the biotechnology company’s stock worth $2,065,000 after buying an additional 29,900 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in Bioverativ during the 4th quarter worth about $3,690,000. Finally, Palo Alto Investors LLC lifted its position in Bioverativ by 25.1% during the 4th quarter. Palo Alto Investors LLC now owns 264,400 shares of the biotechnology company’s stock worth $14,256,000 after buying an additional 53,100 shares in the last quarter. 97.18% of the stock is owned by hedge funds and other institutional investors.
Shares of BIVV stock remained flat at $$104.98 on Friday. Bioverativ has a fifty-two week low of $48.14 and a fifty-two week high of $105.01.
Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.01. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. The company had revenue of $328.70 million during the quarter, compared to analyst estimates of $325.89 million. sell-side analysts anticipate that Bioverativ will post 3.82 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Brokerages Set Bioverativ Inc (BIVV) PT at $64.20” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/brokerages-set-bioverativ-inc-bivv-pt-at-64-20.html.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.